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 Introduction 
 In a book exploring the scope for mutually supportive integration 
between addressing health care needs and promoting industrializa-
tion, Brazil’s experience offers an important case study. 1 This chapter 
presents Brazil’s main strategies to ensure access to medicines to tackle 
the population’s principal health problems. It particularly aims to show 
how the principle of the universality of care has influenced industrial 
policies and production in the pharmaceutical sector. Although more 
than 25 years have passed since Unified Health System ( Sistema  Único de 
 Saúde : SUS) was established, and much progress has been made, a great 
many challenges remain. This chapter focuses particularly on those 
related to access to health technologies. 
 The underlying premise of the Brazilian approach is that health is a 
social right and improving the health of individuals has a positive impact 
on society as a whole. Yet the sustainability of the health system depends 
on a domestic production system capable of producing the needed tech-
nologies for health care. That production system in turn constitutes an 
important economic sector, generating employment and income and 
capable of reducing external dependence in strategic areas. This chapter 
explores how this relationship is configured within Brazilian society, the 
progress made and challenges faced by attempts to guarantee a reduc-
tion in health inequalities, with the aim of increasing policy dialogue 
between Brazilian, African and other policy makers and researchers. 
Brazilian experience in the dissemination of local innovations to meet 
health needs could be learned from and drawn upon by other countries, 
including recognition of the huge challenges that remain. 
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 New medical technologies hold great promise for improvements to the 
population’s health, but they accentuate concerns about the amplifica-
tion of already significant health inequalities, since their consumption 
is determined by a range of factors, including the socio-economic status 
of the patient and the existence of public systems that guarantee patient 
access (Goldman and Smith, 2005). The impact of new technologies on 
health disparities depends on how hard they are to adopt and who effec-
tively receives treatment. They are not uniformly absorbed into health 
systems, nor is there a guarantee of access for all, even in systems with 
universal coverage (Loureiro et al., 2007). 
 In high-income countries, research and development (R&D) efforts 
may result in innovations driven by technology, despite a high degree 
of uncertainty. However, in developing countries, demand constitutes 
the principal stimulus for innovation. From this perspective, the legal 
framework and the organization of health systems may either direct the 
diffusion of technologies towards social interests or allow the process to 
occur in a manner more closely aligned with market interests. 
 For its part, health care is increasingly expensive and dependent on 
a series of technologies such as diagnostic and surgical equipment and 
pharmaceutical products. The factors responsible for significant increases 
in health spending as a proportion of a country’s domestic income and 
which may compromise the sustainability of its health system, include: 
the cumulative nature of the use of medical technologies; the oligopo-
listic structure of the sector, which often includes temporary monopo-
lies obtained via intellectual protection; increases in per capita income 
and life expectancy; and changes to the epidemiological profile. 
 The sustainability of health systems is therefore one of the greatest 
challenges for public administrations at a global level, particularly 
for countries with universal systems such as Brazil, a middle-income 
country. Since 1988, the Brazilian state has considered health as a right 
and its provision as a duty that must be guaranteed to all its citizens; this 
includes pharmaceutical health care, which is considered necessary for 
the guarantee of comprehensive services. 
 Given significant pressure for the systematic incorporation of new 
medicines into the Brazilian health system, the country has sought to 
incentivize the growth of domestic technological capability, reflecting 
the demands of its Unified Health System. From this perspective, inno-
vation within this industry has significant relevance for Brazil’s social 
and economic development and presents huge challenges, given the 
complexity of scientific and technological development activities, 
the political and institutional coordination required, the scarcity of 
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resources and the nature of mechanisms for knowledge production and 
appropriation. 
 This is, therefore, a field that allies economic dimensions with a strong 
social dimension, requiring the mobilization of a broad regulatory and 
institutional apparatus. In this way, despite the crisis in the both the 
Keynesian and the welfare state, health continues to be one of the most 
significant areas of state intervention, both in the service sector and in 
scientific and technological activities (Aragão et al., 2014; Gadelha and 
Costa, 2012). 
 Pharmaceutical health care in Brazil: seeking to link 
economic and social logic 
 The logic of social rights 
 The Unified Health System (SUS) was instituted by the 1988 Federal 
Constitution, as a result of a widespread movement for the democ-
ratization of society and another within the health sector, known as 
Sanitary Reform, which sought to create a public health system for all 
the country’s citizens (Paim, 2009). Since 1988, health has been consid-
ered an inalienable right, and the state is responsible for guaranteeing 
universal, comprehensive and equitable access to activities and services 
that include the prevention of diseases and the promotion and restora-
tion of health. 
 Through the 1988 Federal Constitution, the health system was inte-
grated into the social security system and the social care and welfare 
systems (Federal Constitution 1988, art. 194), becoming a sector without 
restrictions on beneficiaries, where access did not require users’ contri-
bution (Brasil, 1998, art. 196). 
 The interpretation of the concept of social justice in the Brazilian 
Federal Constitution is innovative, since it views social security as ‘an 
integrated series of activities initiated by the public authorities and by 
society, aimed at security rights related to health, welfare and social 
care’, 2 introducing the notion of universal social rights as a condition 
of citizenship. It recognizes social rights and asserts that it is the duty of 
the state to guarantee such rights. 
 In the case of the SUS, universality represents the opportunity for 
all citizens to use public health activities or services without barriers 
to access of an economic, physical or cultural nature; comprehensive-
ness is understood in relation to a series of coordinated and continuous 
preventative and curative, individual and collective activities and serv-
ices, at all levels of system complexity; and equity contains within it a 
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certain notion of justice. It recognizes that individuals are different from 
each other, and therefore deserve differentiated treatment. In this sense, 
access to medicines begins to constitute a right, in that it is a health care 
component at all levels of complexity. 
 The 1990 Organic Health Law ( Lei  Orgânica  da  Saúde : LOS) asserts that 
the execution of comprehensive therapeutic care activities falls to SUS, 
and this includes pharmaceutical health care, given that medicine is 
a strategic ingredient to support health activities and its absence may 
compromise treatment, affecting both the patient’s quality of life and 
the problem-solving capacity of health activities. 
 To secure this, it is envisaged that the SUS, amongst other bodies, 
formulates public policies; develops programmes that enable the popu-
lation’s access to medicines, equipment, vaccines and other supplies to 
meet its health needs; and participates in their production, either directly 
through public laboratories, or indirectly, acting jointly with those 
economic and science and technology bodies aimed at guiding research, 
development and production in the public interest. Furthermore, it 
operates through agreements and partnerships with private pharma-
cies, enlarging distribution channels. This is regarded as a tense arena 
of negotiation between collective and private interests, highlighting the 
need for state action to ensure that the institutional framework func-
tions adequately (Gadelha, 2006; Gadelha et al., 2012; Oliveira et al., 
2006). 
 Brazilian pharmaceutical health care policy 
 The integration of pharmaceutical management with production 
policy is distinctive of the Brazilian approach. To secure its guarantee 
to supply medicines to the Brazilian population, the Ministry of Health 
needed to work with, amongst others, the economic and science and 
technology spheres as core elements in the conduct of policies that 
guarantee the production of pharmaceutical products designed to 
meet SUS needs. 
 Although the right to pharmaceutical health care has been enshrined 
in the SUS since its creation, a specific policy – the National Medicine 
Policy ( Política  Nacional de  Medicamentos : PNM) – was only created 
in 1998. In 2004, this was superseded by the National Policy of 
Pharmaceutical Care ( Política  Nacional de  Assistência  Farmacêutica : PNAF) 
(Brasil, 2004a). Overall, this strategy extends the Brazilian population’s 
access to medicines and is therefore based on the same principles that 
guide SUS. This policy is based on the promotion of the rational use of 
medicines. It includes a range of adjustments to pharmacy practices and 
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regulation, the production of essential medicines and scientific and tech-
nological development. Thus several initiatives were taken to enhance 
the national production of pharmaceutical drugs such as qualifying the 
public laboratories, and incentives to private groups to produce priority 
drugs to meet the SUS demand with financial support from distinct 
governmental agencies and offices other than the health sector. 
 The financing of public pharmaceutical health care programmes is the 
responsibility of the three spheres of SUS management: the federal, state 
and municipal governments. The allocation of resources to finance the 
acquisition of medicines and supplies is organized into three pharma-
ceutical health care components: basic, strategic and specialized. Each 
component includes resources for financing one or more programmes or 
activities, and each has its own features related to planning and admin-
istration. Medicines for HIV/AIDS, cancer and coagulopathy are not 
included within any of these components, but are funded exclusively by 
the federal government. 
 The federal government also bears the cost of supplying medicines 
through the Brazilian Popular Pharmacy ( Programa  Farmácia Popular do 
 Brasil : PFPB) and the  Here There Is a Popular Pharmacy ( Aqui Tem  Farmácia 
Popular ) programmes (described below), which provide certain medi-
cines either free of charge or at low cost, making them more accessible 
to the population (Brasil, 2004b). 
 Links to technological development in medicines 
 With the implementation of the PNM, Brazil expanded a strategic project 
for the technological development of medicines, initially through public 
production of essential medicines by laboratories belonging to the SUS 
(currently 19 SUS public laboratories). Two notable health policies in this 
initial period were investments by the Ministry of Health to allow public 
laboratories to produce less-expensive versions of anti-retroviral drugs, 
beginning in 1996, and the implementation of the Generic Medicines 
Law in 1999. 
 Brazil’s policy of universal access to free anti-retroviral treatment 
supplied directly to the public sector has been in force since 1996, and has 
been an exemplary model for global efforts to reduce the HIV epidemic. 
However, it has also involved a significant increase in Ministry of Health 
spending on medicines, which rose from approximately US$35 million 
in 1997 to a landmark US$305 million in 1999 (Loyola, 2008). The vast 
majority of these medicines were imported, implying that fluctuations 
in the dollar led to interruptions in supply. The response was investment 
in the domestic production of medicines. 
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 This initiative inaugurated the systematic establishment of agree-
ments between the public and private sectors for the transfer of tech-
nology to public laboratories that manufacture medicines. Currently, 
the country is capable of producing 10 of the 23 medicines that 
constitute the HIV/AIDS treatment cocktail. Farmanguinhos alone, 
the Oswaldo Cruz Foundation (FIOCRUZ) Laboratory and part of the 
Ministry of Health, produces and distributes seven of the ten anti-
retroviral drugs produced in the country (Fiocruz, 2014). FIOCRUZ is 
the largest public health institution in the country, for research, educa-
tion, health care, development and pharmaceutical drugs production. 
Farmanguinhos is the unit for the production of pharmaceutical chem-
icals, and Biomanguinhos for the production of biologicals. These 
units, like others public laboratories, supply the specific programmes 
of the Ministry of Health. 
 The Generic Medicines Law enabled competition on the part of the 
public and private domestic industry in the market for drugs with 
expired patents. On the other hand, from 1996 onwards, the Patent 
Law (1996) recognized pharmaceutical patents in Brazil by adhering 
to the Trade-Related Aspects of Intellectual Property Rights (TRIPS). 
This had a negative impact on the domestic industry, one of whose 
competitive pillars was the commercialization of similar medicines 
(copies of the branded drugs) and which could not compete with 
the large international oligopolies in the production of innovative 
medicines. The domestic market configuration changed as a result. 
National companies focussed on the production of generic versions 
and multinationals increased their share in reference products that are 
more expensive that generic versions (Capanema and Palmeira, 2004; 
Gomes et al., 2014) 
 Strengthening industrial policy for pharmaceuticals 
 However, the right to pharmaceutical assistance within the SUS and 
the need to provide essential products to the Brazilian population at 
accessible prices required a series of measures to strengthen the phar-
maceutical industry in Brazil, particularly in sectors serving the prin-
cipal public health requirements. In the face of these challenges, the 
strengthening of the pharmaceutical chain became a strategic objective 
of Brazil’s industrial and development policies. 
 Several public bodies, including the National Development Bank 
( Banco  Nacional de  Desenvolvimento: BNDES), started to support the devel-
opment of the country’s pharmaceutical chain. The Support Program for 
the Development of the Pharmaceutical Productive Chain ( Programa de 
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 Apoio à  Cadeia  Farmacêutica : ROFARMA), launched in 2004, provided 
specific BNDES credit support to contribute to growth in the domestic 
pharmaceutical industry. 
 Between 2004 and 2013, BNDES invested almost 5 billion Brazilian 
Reals in approximately 110 operations, spread across lines of support 
aimed at production, innovation, restructuring and biotechnology, and 
focusing on domestically owned companies and public laboratories. In 
its first phase, PROFARMA constituted an important source of funds to 
ensure that the national pharmaceutical complex complied with the 
new regulatory demands, which had become much more rigorous after 
the 1999 creation of the National Health Surveillance Agency ( Agência 
 Nacional de  Vigilância  Sanitária : ANVISA). However, throughout its exist-
ence, the programme adapted to industry needs, focusing on the produc-
tion of generic medicines, on innovation and on the development of 
biotechnology, due to the increasing application of biopharmaceuticals 
in the treatment strategies for a range of diseases, particularly chronic 
non-communicable illnesses (Palmeira Filho et al., 2012). 
 These and other initiatives resulted in increased investment in 
research and development (R&D) within the Brazilian pharmaceutical 
industry. According to the Survey of Technological Innovation ( Pesquisa 
de  Inovação : PINTEC), in 2003, R&D investment by the pharmaceutical 
industry corresponded to 0.5% of net revenue, slightly lower than indus-
trial sector average. In 2011, this had risen to 2.4% of net revenue, while 
the average for the industrial sector remained at around 0.7% (PINTEC/
IBGE, 2011). 
 Local production for domestic requirements 
 The combination of the legal framework and the SUS organizational 
system has sought to direct the diffusion of technologies towards social 
interests, rather than allowing the process to occur in a manner aligned 
only with market interests. The data show that the investments in the 
pharmaceutical supply chain have been reflected in the consolidation 
of the local generic medicine sector. Since 2004, the total pharmaceu-
tical market in Brazil has grown exponentially, both in number of units 
sold (9% per annum) and in real value (10% per annum), reaching 
almost R$ 40 billion in 2013 (Gomes et al., 2014; Interfarma, 2014). 
The market for generic medicines has provided a significant element 
of this growth, since in terms of unit sales, generic drugs’ share of total 
sales leapt from 9% in 2004 to 27% in 2013 (Figure 9.1), while sales 
of both brand-name drugs and similar drugs fell (Gomes et al., 2014; 
Kaplan et al., 2013). 
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 As the Gomes et al. (2014) study points out, the opportunities gener-
ated by the dynamism of the internal market, increasing improvements 
to sanitary regulation in Brazil and public policies have all been exploited 
by domestically owned companies, whose domestic market share rose 
from 30% at the beginning of the 2000s to over 50% in 2012. 
 In 2013, five Brazilian pharmaceutical companies were among the ten 
biggest companies in the Brazilian national market, measured by total 
sales. Generic drugs had almost 30% of the Brazilian market, measured 
in units sold, 15% by total sales. Furthermore, 85% of the drugs available 
in the Popular Pharmacy Program are generic drugs. As regards the origin 
and ownership of the capital invested, about 90% of the companies 
producing generic drugs are Brazilian, 6.3% are from India, 0.8% from 
Germany, 0.6% are Canadian and 0.5% Spanish (Progenericos, 2014). 
 The share of household income spent on medicines is higher in Brazil 
for those on lower incomes. Medicines account for 4.2% of spending 
in households with a monthly income of up to US$452.20. This corre-
sponds to 76.4% of health expenditure for households within this 
income bracket. For those with a monthly income over US$5,655.20, 
spending on medicines is only 1.9% of income (IBGE-POF, 2008–09). 
Therefore, the SUS is a decisive instrument for the reduction of inequali-
ties, in coordination with the economic and science and technology 
fields, and for the promotion of health as a priority for the sustainable 

























 Figure 9.1  The Brazilian pharmaceutical market (unit sales), 1997–2013 
 Source : Drawn by the authors from data sourced from Progenericos (2014) and Gomes et al. 
(2014). 
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 Public demand and domestic medicines production 
 The enlargement of the state’s purchasing power has been a funda-
mental strategy for extending access to medicines and strengthening 
the production base to address SUS interests, both public and private. 
Out of a range of important inter-sectoral initiatives (Aragão et al., 2014; 
Gadelha and Costa, 2012), two programmes particularly help to under-
stand how current initiatives to strengthen the health sector in Brazil 
have had an impact on the domestic production of medicines. 
 The first, the Brazilian Popular Pharmacy Programme ( Programa 
 Farmácia Popular do  Brasil : PFPB), was established in 2004 within the 
Ministry of Health in order to extend the population’s access to essen-
tial medicines. It was hugely important in the growth of the generic 
medicines sector in Brazil, since its establishment relied heavily on the 
extension of the domestic production base. The second, the Partnerships 
for Productive Development ( Parcerias  para o  Desenvolvimento  Produtivo : 
PDPs), begun in 2012, aimed to strengthen the domestic pharmo-chem-
ical and medicine industries, particularly in more innovative areas such 
as biotechnology, in order to reduce external dependence in key stra-
tegic areas. 
 Industrial policy in Brazil generally recognizes the potential of public 
procurement to promote competition in markets where government 
demand is significant, such as health. Rules have been defined for the 
use of public purchasing power, which allow a price preference of up to 
25% for purchases from domestic producers, using a method of calcu-
lation that takes into account employment and income generation, 
impact on tax revenues, national development and other factors. 3 
 The Brazilian Popular Pharmacy Programme (PFPB) 
 The PFPB expanded access to medication for the most common diseases, 
benefitting people on low incomes and enabling access to low-cost 
medicines for users of the private health network. Federal government 
initiatives included centralization of the medicines procurement and 
administrative improvements. Medicines were acquired, distributed and 
managed centrally by FIOCRUZ, a unit of the Ministry of Health. This 
procurement strategy was underpinned by a guarantee of state funding. 
 In order to meet the pharmaco-therapeutic needs of PFPB users, 
the Ministry of Health established a list of medicines based on the 
National Essential Medicines List, which was defined using epidemio-
logical criteria, taking into account the principal diseases that affect the 
Brazilian population and the treatments that have the greatest impact 
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on household budgets. The list also considers the medicines contained 
within the Ministry of Health’s Welfare Programmes, the production 
capacity of the Official Pharmaceutical Laboratories and registration as a 
generic medicine (Brasil, 2005; 2010). 
 Initially restricted to the SUS network, from 2006 the Programme was 
extended to the private sector through partnerships with pharmacies. 
In 2011, with the launch of the Brazil Without Extreme Poverty Plan 
( Plano  Brasil  Sem  Miséria ), the municipalities included in this plan to 
eradicate extreme poverty were prioritized by the PFPB, in line with 
criteria adopted by the Ministry of Social Development and Combating 
Hunger. 
 Given the country’s epidemiological profile, one programme priority 
is to extend access to hypertension and diabetes medication. About 
33 million Brazilians have been diagnosed with hypertension and 
80% (or approximately 22.6 million hypertension sufferers) are treated 
within the public health network. According to 2011 data, more than 
7.5 million Brazilians have a diabetes diagnosis and about 6 million of 
these patients are treated within the public system. These diseases are 
included in the risk factors for cardiovascular problems, the greatest 
cause of mortality in Brazil (WHO, 2012). Through the activities of the 
PFPB aimed at non-communicable diseases (NCDs), medicines for the 
treatment of hypertension, diabetes and, latterly, asthma began to be 
dispensed to patients free of charge. In 2011, respiratory diseases were 
the third cause of death in the country (MS/PFPB, 2014; WHO, 2012). 
 Currently, the PFPB provides access to essential medicines for a wide 
range of patients with a private medical prescription, complementary to 
SUS, at low cost or free of charge. The initial list of medicines included 84 
pharmaceuticals, dispensed to the population using their generic names, 
representing more than 1,200 commercial medicine brands registered in 
the pharmaceutical market. The PFPB provides for the inclusion of new 
products and takes into account regional variations, given its territo-
rial coverage and the diversity of the epidemiological profiles across the 
different regions of the country. The first additions to the PFPB list of 
medicines occurred in 2004, when seven new items were added. Since 
then, new updates to the list have been made in order to increase its 
coverage. By 2013, more than 550 medicines had been made available 
(Brasil, 2004b; MS/PFPB, 2014). 
 It is worth noting that the products distributed through the PFPB are 
acquired through specific procurement processes, not to be confused 
with public procurement by federal, state, federal district and munic-
ipal governments. The programme prioritizes purchase of medicines 
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produced by official government laboratories (public industrial units) 
and generic medicines (acquired through a bidding process); a pharma-
ceutical’s availability as a generic medicine is therefore a factor for inclu-
sion into the PFPB medicine selection process. 
 The expansion of the PFPB budget, of the accredited network and of 
the number of municipalities served has both reflected demand and 
coincided with growth in the generics market in Brazil (Figure 9.2). 
 By March 2015, more than 33,000 establishments had been accredited 
by the PFPB, distributed across 4,351 of the 5,570 Brazilian municipali-
ties and providing almost 80% coverage in municipalities with Popular 
Pharmacy establishments. This is in contrast to 2006, when 2,955 
establishments were accredited in 594 municipalities, with coverage of 
only 11% of municipalities. To this end, the programme’s budget has 
increased significantly over the years. 
 Federal spending on the PFPB, in real terms in 2013 prices, has jumped 
from a little over R$35.7 million in 2006 to R$879.5 million in 2011, 
R$1.4 billion in 2012 and R$1.9 billion in 2013. In 2013, total spending 
on medicines rose to slightly over R$10 billion (Sala de Situacão em Saude, 
2015). These data demonstrate the programme’s importance and the 
need to coordinate it with production development policies, since rising 
demand has driven the increased production of generic medicines. 
 In turn, the Ministry of Health budget grew from R$59 billion in 2006 
to R$100.5 billion in 2013, also in real terms. By 2013, the amount 









 Figure 9.2  Percentage of municipalities covered by the PFPB, 2006–15 
 Source : Drawn by the authors from data from Sala de Situacão em Saude (2015), accessed 8 
March 2015. 
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spent on medicines represented more than 10% of the total Ministry of 
Health budget. Public purchasing is responsible for 30% of the country’s 
demand for medicine (Interfarma, 2014). 
 Strengthening public industrial production units has been a strategy 
to secure production in less intensive knowledge areas, such as generic 
products, in several Ministry of Health programmes. This approach also 
applies in more intensive knowledge areas, such as biological products, 
where the proportion of total Ministry of Health medicines expenditure 
has grown significantly, due to high prices, and contributed to the health 
sector’s trade deficit. The Partnerships for Productive Developments 
(PDPs) were launched as a response to this. 
 Inter-sector coordination has enabled the creation of significant regu-
latory frameworks, which have tended to have a positive impact on the 
strategic sectors for the country’s development. Significant features of 
these regulatory frameworks of support for innovation are Law 10973 
of 2004 (Brasil, 2004c), known as the Innovation Law, 4 and the Goods 
Law of 2005 (Brasil, 2005), which were important for the development 
of Brazil’s health-related goods industry. Furthermore, the PDPs have 
been the object of inter- and cross-sector policies aimed at reducing 
external dependency, in favour of innovation and the extension of 
domestic capacity to produce strategic technologies, including biologi-
cals, for SUS. 
 Partnerships for productive development ( Parcerias  para o 
 Desenvolvimento  Produtivo : PDPs) 
 The PDPs form part of the policies in the Greater Brazil Plan, which 
contains guidelines that focus on innovation and productivity growth in 
the Brazilian industrial complex. They are one of the components of the 
Programme for Investment in the Health Industrial Complex ( Programa 
de  Investimento no  Complexo Industrial  da  Saúde: PROCIS). The latter was 
launched in 2012 to coordinate the national strategy for development 
and innovation in health through investment in public producers and 
in public infrastructure for production and innovation. It is thus aimed 
at strengthening Brazilian industry, providing the country with greater 
autonomy for the production of strategic SUS technologies. 
 There are currently 19 SUS public laboratories involved in PDPs. They 
are responsible for the production of medicines, serum and vaccines to 
meet the country’s public health needs. However, many products are 
still imported from other countries, and gaps in domestic production as 
well as the high cost of medicines may hinder access. Through PROCIS, 
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the Ministry of Health has invested in public companies’ infrastructure 
and workforce training (MS/DECIIS, 2015). 
 The partnerships are established between public drug production 
companies and the private production sector, aiming to absorb the tech-
nology to make new formulations. Thus, foreign companies with tech-
nological dominance commit to transferring to domestic companies 
the technology required to produce the medicine, as well as to produce 
within the country, to some degree, the active pharmaceutical ingredi-
ents (APIs) (the substance responsible for the treatment), over a five-year 
period. In return, the government guarantees exclusivity in procuring 
these products – at values below those quoted in the global market – 
over the same period. Until this point, since 1985, when the self-suffi-
ciency programme in immunobiologicals was launched, there had been 
no other stimulus or public production investment programmes (Brasil, 
2012 – Portaria nº 837/2012). 
 At the end of the technology transfer period, the domestic public labo-
ratory will initiate autonomous production of the medicine in order to 
meet domestic demand. With production conducted inside the country, 
public laboratories will begin reducing dependence on imports (as illus-
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 Figure 9.3  Pharmaceutical products: Balance of trade, Brazilian exports and 
imports (US$ billion FoB) 
 Source : Drawn by the author from data from MDIC/Secex/Sistema Alice apud, INTERFARMA, 
2014. 
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 As well as generating significant savings for the Ministry (estimated at 
approximately R$4 billion a year) and reducing the country’s dependence 
on importing products (Figure 9.3), the partnerships signed thus far have 
also benefitted the population, since they guarantee the supply of essen-
tial medicines to the SUS network. In 2012, more than R$250 million 
was invested in public pharmaceutical companies’ infrastructure and 
workforce training – more than five times the average investment for 
the previous twelve years (R$42 million). Between 2000 and 2011, total 
government investment was R$ 512 million. 
 At the end of 2014, the Ministry of Health was involved in 104 product 
development partnerships, involving 19 public and 57 private laborato-
ries. These agreements provide for the development of 101 products (66 
medicines, 7 vaccines and 28 other health products). 
 Partnerships are focussed on the production of biological medicines, 
which have an average value significantly higher than traditional medi-
cines and are principally used for the treatment of non-communicable 
diseases, such as various types of cancer and rheumatic problems. 
Although biological medicines represent approximately 5% of the medi-
cines purchased by the Ministry of Health (measured by unit sales), they 
represent 49% of spending. Importing these products has been one of the 
main reasons for the increase in the health trade deficit, which leapt from 
approximately US$1 billion in 1997 to more than US$5 billion in 2013. 
 Reducing dependence on imported biopharmaceuticals by taking 
advantage of the predicted expiry of a series of product patents over 
the next few years may extend the population’s access to treatments for 
those diseases for which the technology is demonstrably more effective 
than traditional medicine. In 2015, more than 25 biopharmaceutical 
products are available in SUS for the treatment of cancer, rheumatoid 
arthritis and other chronic diseases. Almost all are in the process of tech-
nology transfer to the national public companies. 
 In the specific case of cancer, the ability to introduce biopharmaceu-
ticals for treatment has proven to be important in reducing inequality 
in access to this type of treatment. The Aragão et al. (2012) study 
demonstrated that biopharmaceuticals not incorporated into SUS were 
usually accessed via legal proceedings and that their implementation 
was restricted to such demands, prioritizing users of the private health 
system. In 2010, the federal government spent US$3.4 million on 
responding to judicial demands related to the supply of biological thera-
pies to treat cancer; since 2012, some of these have been incorporated 
into SUS. This signifies per capita spending of up to US$183,300 in 2009 
and 2010. 
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 The public health system is responsible for the treatment of approxi-
mately 80% of cancer cases in Brazil. From 1999 to 2010, federal expend-
iture on chemotherapy alone rose in real terms from R$780 million to 
more than R$1 billion. In 2010, total expenditure, including spending on 
radiotherapy, surgery and radioiodine therapy, passed a landmark R$1.5 
billion, or US$852 million (Aragão et al., 2014; MS, 2011). Spending 
on oncology medication represented more than 10% of total spending 
on medicines, with the largest burden coming from the acquisition of 
biological medication. With the exception of immunobiologicals (serum 
and vaccines) and one group of high-cost medicines aimed at a broad 
range of rare pathologies, oncology drugs accounted for the largest share 
of total Ministry of Health spending on medicines. Biopharmaceuticals, 
which will be produced through PDPs, currently represent R$1.8 billion 
per year of Ministry of Health public procurement expenditure (MS/
DECIIS, 2015). 
 In the case of cancer, considered here as an example, one needs to 
remember that treatment based on biological medicines is very costly, 
given that this is a high-complexity production category and, there-
fore, one with higher costs. Furthermore, it is more difficult to copy 
biological medicines once their patents have expired. Unlike chemicals, 
which may be copied as a whole, proteins are not amenable to identical 
copying; such copies are therefore biosimilar and require specific regula-
tion. Moreover, companies in this sector have extremely high powers 
of negotiation, given the market concentration in a very small set of 
businesses. 
 Making use of public purchasing power and establishing policies to 
promote the domestic pharmaceutical industry, including public labo-
ratories, are strategies to protect against the monopolistic practices 
exercised by the large pharmaceutical companies. These practices are 
made possible by a regime of intellectual protection highly favourable to 
economies in developed countries. In a sector in which the substitution 
of goods is highly limited, the persistence of such practices will certainly 
deepen social inequalities at both international and national level. From 
this perspective, policies that take into account the degree of market 
concentration may ensure the introduction of innovative technologies, 
while at the same time reducing inequalities in access to medicine. 
 Concluding reflections 
 Since the promulgation of Brazil’s 1988 Constitution, significant 
progress has been made in improving the population’s access to health 
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services, including to pharmaceutical health care. A series of legal and 
regulatory frameworks have been established in order to guarantee the 
free or subsidized provision of medicine to the population. To guarantee 
the domestic production of essential products, the Ministry of Health 
has become the country’s central pivot in ensuring the local develop-
ment of production capacity in order to develop technologies to meet 
SUS needs. 
 The Ministry of Health has managed to use its purchasing power to 
guide public and private investment in the interests of the SUS. This has 
reduced the main risk of technological innovation, which is the absence 
of a market. Product Development Partnerships have had huge success in 
transferring technology from the private sector (particularly the sector’s 
large company leaders) to the public sector, which receives the tech-
nology and jointly develops the ingredients. Thus, even if production is 
shared with the private sector, the technology domain has moved to the 
public sector, as the regulatory framework indicates. However, the final 
results of the new model of partnerships established from 2012 should 
also be evaluated in the future, in relation to the ability to internalize 
the skills for production of APIs. Previous partnerships between private 
and public companies, as in the case of anti-retroviral drugs, allowed 
domestic production, but the country continued to depend on imports 
of the APIs. 
 What we observe is the construction of public policies to guide a 
range of health industry actors towards a social need, in this case the 
demand for medicine. To achieve this, the Ministry of Health has begun 
to coordinate policies traditionally regarded in Brazil as belonging to the 
economic sphere. Such orientation shifts the production logic of capi-
talist reproduction guided by the market, directing public and private 
investment towards the production of goods aimed at meeting SUS’s 
priority health needs. 
 Such initiatives have led to successful actions, such as improved access 
to treatment for HIV/AIDS, cancer, diabetes, hypertension and a series of 
other diseases prevalent in the country, either through direct SUS provi-
sion or mediated through the PFPB in the form of free or low-cost distri-
bution through the country’s network of pharmacies. These initiatives in 
turn have contributed to the development of a domestic generic medicine 
industry capable of producing technologies to meet public and private 
health demands at competitive prices, as well as developing production 
capacity in more innovative areas, such as biopharmaceuticals. 
 The use of procurement powers and the policies to incentivize the 
domestic pharmaceutical industry, including public pharmaceutical 
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companies, are forms of protection from the monopolistic practices exer-
cised by the large pharmaceutical corporations. Such practices are made 
possible through an intellectual protection regime which is extremely 
favourable to the economies of high-income countries. In a sector in 
which the substitution of goods is extremely limited, the persistence of 
such practices clearly deepens social inequalities at both national and 
international level. 
 However, huge challenges remain. The country remains a large-scale 
importer of pharmaceuticals and medicine. The construction of internal 
production capacity to reduce external dependency is a long-term 
process, involving heavy investment. 
 The production of generic medicines is extremely important in 
meeting domestic health needs, but it does not help to reduce the deficit 
because it is based on the import of active ingredients and, in certain 
cases, of formulations which are then combined. There is now a need 
for a policy that enables Brazilian companies to grow and acquire know-
how in the development of generic medicines so they can make the leap 
towards the production of a more intensive local technology synthesis 
and broaden their portfolio of similar and innovative medicines for the 
market. 
 Notes 
 1 .  The research project that was the basis for this chapter received finan-
cial support from the National Council for Technological and Scientific 
Development (CNPq) through a grant to the Instituto Nacional de Ciência 
e Tecnologia em Saúde (CITECS) – National Institute of Science and Health 
Technology. The authors would like to thank Cressida Evans for the transla-
tion into English from the Portuguese version of this paper. 
 2 .  Federal Constitution law: Article 194: Social security encompasses a set of 
integrated actions by the public power and the civil society geared to assure 
the rights related to health, social security and social assistance. Article 196. 
Health is a right assured to all citizens and a state duty warranted through 
social and economic policies with the objective of reducing the risk of disease 
and other health impairment, and universal and egalitarian access to health 
actions for prevention, protection and recovery care (Brasil, 1988). 
 3 .  Law 12349/2010 and regulated by Decree 7546/2011. 
 4 .  Redrafted in Law no 12349, 2010. 
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